Avalyn Pharma Inc. (AVLN) – What Are Investment Firms Thinking About This Stock?

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $59.20.

Several equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday, November 11th. Raymond James Financial began coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They issued an “outperform” rating and a $60.00 target price for the company. Wall Street Zen upgraded Avalyn Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Finally, Morgan Stanley reduced their price target on Avalyn Pharma from $57.00 to $53.00 and set an “overweight” rating on the stock in a research note on Monday.

View Our Latest Stock Analysis on AVLN

Insider Activity

In other Avalyn Pharma news, insider Fmr Llc sold 175,000 shares of Avalyn Pharma stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $29.07, for a total value of $5,087,250.00. Following the completion of the sale, the insider owned 2,109,535 shares in the company, valued at $61,324,182.45. The trade was a 7.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Howard Lazarus sold 13,300 shares of the stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $27.90, for a total transaction of $371,070.00. Following the transaction, the insider owned 13,300 shares in the company, valued at approximately $371,070. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 241,754 shares of company stock worth $7,073,165 over the last quarter.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in Avalyn Pharma during the third quarter valued at approximately $29,000. Manchester Capital Management LLC purchased a new stake in Avalyn Pharma during the third quarter worth approximately $36,000. Algert Global LLC acquired a new stake in shares of Avalyn Pharma in the third quarter worth $465,000. Profund Advisors LLC acquired a new stake in shares of Avalyn Pharma in the third quarter worth $668,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Avalyn Pharma in the second quarter worth $1,321,000.

Avalyn Pharma Price Performance

Shares of NASDAQ:AVLN opened at $28.70 on Friday. The business’s fifty day moving average price is $28.03 and its two-hundred day moving average price is $29.88. The stock has a market cap of $1.28 billion and a PE ratio of -1.22. The company has a debt-to-equity ratio of 0.04, a quick ratio of 25.76 and a current ratio of 25.76. Avalyn Pharma has a one year low of $22.24 and a one year high of $40.17.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03). On average, analysts forecast that Avalyn Pharma will post -3.87 EPS for the current fiscal year.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.

Featured Stories

Analyst Recommendations for Avalyn Pharma (NASDAQ:AVLN)

Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.